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Yacute myocardial infarction. In addition subjects with B2/C lesions, which are
known to have a higher risk for cardiac complications or restenosis have been
evaluated.
RESULTS Nine hundred seventy one men (72%) and three hundred eighty ﬁve
women were enrolled at 43 sites in 14 countries. The mean age was 66.1  10.7,
ranging from 29 - 91 years. The majority of subjects presented with hypertension 76%,
hypercholesteremia 60%, smoker 55%, and diabetes 30%. 48% of all stented vessels
had a diameter 2.75mm, 4% presented with chronic total occlusion. Eleven percent
of the subjects experienced unstable angina, 47% stable angina. Acute MI was seen in
33% of the subjects (NSTEMI 22%, STEMI 11%). The portion of elderly subjects (75
years) is represented by 25%. An unbiased patient population was seen in the registry
with more than 52% type B2/C lesions. Moderate and severe calciﬁcation was
observed in 31%. The Orsiro hybrid stent system demonstrated excellent device
(98.7%) and procedure success (98.2%). In this all-comers setting a TLF rate of 5.1%
was observed within the ﬁrst 12 months. The low TLF rate was also conﬁrmed for the
subgroups: diabetics (7.7%), acute MI (7.2%), small vessel (5.8%), CTO (1.8%) and
complex B2/C lesions (5.1%).
CONCLUSION The results observed in this “real world” population demonstrate a low
TLF rate comparable to other state of the art DES at 6- and 12-months.
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OBJECTIVES BIOFLOW-II is a randomized controlled study, comparing the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience Prime) at 2 Years in the complete study population
as well as in the diabetic and small vessel subgroups, which are known to have a
higher risk for cardiac complications. Here we present the outcome through the
clinical endpoints Target Lesion Failure (TLF) and Stent Thrombosis (ST).
METHODS A total of N¼452 subjects (62.710.4, 38-80 yrs) were enrolled in the
Intention to Treat population in the BIOFLOW-II study, registered at clinicaltrials.
gov (NCT01356888). All subjects were stratiﬁed for diabetes and then randomly
assigned (2:1) to receive the Orsiro or the Xience Prime stent. The diabetic subgroup
accounted for 28.3% N¼128 (Orsiro N¼84, Xience Prime N¼44) of all subjects. The
small vessel cohort included all subjects with a reference vessel diameter 2.75mm,
accounting for 57.3% N¼259 (Orsiro N¼168, Xience Prime N¼91) of all subjects.
Clinical follow up visits are performed at 1, 6, 12 months and annually up to 5 years
after the procedure. All angiographic images were analyzed by an independent
Corelab. All clinical events were adjudicated by an independent clinical events
committee.
RESULTS All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The TLF rate at 24 months was 8.4% for the Orsiro vs. 10.0% for
the Xience Prime in the full cohort, 9.7%vs. 9.1% in the diabetic subgroup and 9.4%
vs. 13.3% for subjects with small vessel lesions. There was no statistical signiﬁcance
between the two study arms in any of the three analyzed populations. No ST
(deﬁnitive, probable or possible) occurred through 24 months in the Orsiro arm.
Conclusion In this RCT the clinical event rates of the Orsiro SES with a biodegradable
polymer were low and comparable to the Xience Prime up to 24 month in all three
analyzed populations.
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BACKGROUND The aim of this study is to investigate whether age increase affects the
decision to use drug-eluting stents (DES) in elderly patients undergoing percutaneous
coronary intervention (PCI).METHODS This is a single center registry including elderly patients ( 65 year-old)
undergoing PCI. We deﬁned ﬁrst DES era as the period between April 2003 and July
2008, and second DES era the period of July 2008 to March 2014. Multivariable model
was created for both eras to assess the independent factors associated with DES im-
plantation and the impact of age (per 10 year increase).
RESULTS A total of 8,598 elderly patients were included, of whom 4,528 (52.7%) and
4,070 (47.3%) underwent PCI in the ﬁrst and second generation DES eras, respec-
tively. Multivariable logistic regression showed that age increase of per 10 years was
associated with less likelihood to receive DES implantation. Similarly, patients with
acute myocardial infarction, chronic renal insufﬁciency, chronic heart failure, cardiac
shock and current smoking were less likely to receive DES in the two DES eras.
CONCLUSION Among elderly patients undergoing PCI, age is independently associ-
ated with a lower likelihood of DES implantation in the second generation era. This
ﬁnding may highlight the clinical difﬁculty in assessing the risk/beneﬁt balance of
DES in the elderly population.
Table I. Adjusted Multivariate Logistic OutcomeCRT-158
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BACKGROUND We previously reported that the incidence of 1-year major adverse
cardiac events (MACE) in patients treated with paclitaxel-eluting stents (PES) was
lower than that in the sirolimus-eluting stents, mainly due to reduction of target
lesion revascularization (TLR) in dialysis patients. However, it is unclear whether
there are differences in clinical outcomes between everolimus-eluting stents (EES)
and PES in dialysis patients.
METHODS Between February 2010 and September 2013, 248 maintenance dialysis
patients were treated with coronary stents. In this study, 102 maintenance dialysis
patients with 135 lesions treated with EES were compared to 107 maintenance
dialysis patients with 147 lesions treated with PES. Of these, 60 patients were pro-
spectively randomized to either EES (32 patients) or PES (28 patients) between March
2011 and September 2013. Angiographic and 1-year clinical outcomes were
investigated.
RESULTS Diabetes mellitus (DM) was present in 64.7% in the EES group and 71.0% in
the PES group (p¼0.33). Dialysis period was 6.4  6.3 years vs 6.2  5.9 years
respectively (p¼0.77). Heavy calciﬁcation was in 27.4% vs 34.0% (p¼0.23). In-stent
restenosis lesion was in 14.1% vs 10.9% (p¼0.42). There were no signiﬁcant differ-
ences in reference diameter (2.62  0.64mm vs 2.66  0.60mm, p¼0.52) and lesion
length (15.0  12.2mm vs 16.5  11.4mm, p¼0.29). Rotational atherectomy was un-
dergone in 11.1% vs 23.1% (p<0.01). Total stented length was not signiﬁcantly
different (23.5  14.6mm vs 24.4  13.2mm, p¼0.60). One patient in the EES group
was lost to follow up. Angiographic follow-up was obtained in 73.3% vs 74.8%
(p¼0.77). Restenosis rate was not signiﬁcantly different (18.2% vs 13.6%, p¼0.37). At
12 months, MACE occurred in 13.2% in the EES group and 17.4% in the PES group
(p¼0.25). TLR was observed in 9.5% vs 10.4% respectively (p¼0.77). Mortality was
11.8% vs 13.1% (p¼0.35). Cardiac death was 5.0% vs 7.7% (p¼0.09). Deﬁnite stent
thrombosis was observed in 2.0% vs 0% (p¼0.14). Subgroup analysis in patients with
DM revealed no signiﬁcant differences in MACE (12.7% vs 14.9%, p¼0.36), TLR (8.3%
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Yvs 7.4%, p¼0.42), mortality (13.7% vs 13.2%, p¼0.28), and cardiac death (6.3% vs
8.0%, p¼0.15) between the two groups. Subgroup analysis in randomized patients
showed no signiﬁcant differences in MACE (9.4% vs 18.4%, p¼0.39), TLR (3.3% vs
12.0%, p¼0.17), mortality (6.3% vs 14.3%, p¼0.20), and cardiac death (6.3% vs 7.3%,
p¼0.90).
CONCLUSIONS One-year clinical outcomes following EES and PES implantations are
similar in dialysis patients.
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BACKGROUND Swine model plays an instrumental role in the assessment of vascular
healing response to implantable device. Restoration of vasomotion has been reported
as a key feature of following DES with biodegradable polymer and fully bioabsorbable
scaffold. So far, evaluation of invasive vasomotion response to acetylcholine (Ach) in
naïve health miniswine coronary is lacking. Therefore, we aimed to study the vaso-
motion response in cath lab setting.
METHODS Seventy coronary arteries (LAD¼24, LCX¼23 and RCA¼23) from 30 healthy
adult animals underwent vasomotor function evaluation. Endothelium-dependent
function was assessed by infusion of incremental Ach at doses of 10-6 and 10-5 mol/L.
Followed by baseline angiography, Ach was administrated via a coronary infusion
catheter (Ultra-Fuse, Boston Scientiﬁc) in proximal of artery with 1 ml/min for 2min.
Coronary angiography was performed 30s after each dose with 5min intervals.
Endothelium-independent function was evaluated by NTG (200mg). The mean
luminal diameter of mid-artery in a length of 20mmwas measured by QCA. Responses
to infusions of Ach and NTG were expressed as percentages of diameter changes from
baseline.
RESULTS Animals were tolerated well without hemodynamic and other complica-
tions during test. There were no differences of lumen diameter among groups from
baseline angiograph (LAD, 2.750.29mm; LCX, 2.670.31mm; and RCA,
2.670.21mm; p>0.05 respectively). However, dilation of right coronary artery
(RCA,3.34.3%) was signiﬁcant more than both LAD (0.54.6%, p¼0.02) and LCX
(-1.24.2%, P¼0.002) in response to low-dose of Ach. All of the three epicardial ar-
teries had a mild vessel constriction instead of dilation to response the high-dose of
Ach. No difference was detected regard the percentage of diameter changes
(LAD, -3.97.9%; LCX, -4.57.9%; and RCA, -5.713.8%; p>0.05 correspondingly).
NTG-induced endothelium-independent vasorelaxation was comparable between
LAD and RCA (6.755.9% and 6.65.4%; p>0.05). LCX (3.35.2%) relaxation was
signiﬁcantly less in response to NTG when compared to LAD and RCA (p¼0.04,
individually).
CONCLUSIONS Healthy adult miniswine is FDA accepted model to evaluate novel
coronary device in preclinical study because their size and anatomy are comparable to
human. The data demonstrated that dilation of epicardial vessels in response to
endothelium-dependent Ach challenge is only occurred at lower dose. The preclinical
implications of these ﬁndings are potentially useful for design pf preclinical vaso-
motion study.
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BACKGROUND While drug-eluting stents (DES) have recently improved their efﬁcacy
and safety proﬁles, differences in stent deliverability among various coronary stents
have not been systematically evaluated. The aim of this bench test study was to
evaluate the impact of stent length on stent deliverability between ﬁrst and second
generation DES systems.
METHODS Three coronary stent systems (Bx Velocity, Integrity and Multi-link 8),
using 6 of each, were assessed with 3 bench test models: 135 degree (simple model),
90 degree (complex model) and coronary model (coronary). Stent delivery systems
were inserted into each model using a dedicated machine and the delivery force was
computed, measured, and compared.
RESULTS For ﬁrst generation DES, long stent systems showed deliverability with
signiﬁcantly greater force compared with short stent systems regardless of bench test
model. For second generation DES, complex and coronary model showed similar force
for both short and long stent, however, simple model revealed greater force in long
stent systems compared with short stent systems.
CONCLUSION Our results suggest that second generation DES platforms overall are
more deliverable, requiring less force, than ﬁrst generation DES platforms.CRT-161
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BACKGROUND Coronary stent deployment outcomes can be negatively impacted by
inaccurate lesion measurement and inappropriate stent length selection (SLS). We
compared the manual measurement of these parameters to those provided by the
CorPath 200 Robotic PCI System.
METHODS Sixty consecutive patients who underwent coronary stent placement uti-
lizing the CorPath System were evaluated. The treating physician assessed orthogonal
images and provided visual estimates of lesion length and SLS. The robotic system
was then used for the same measures. SLS was considered to be accurate when
manual and robotic measures were in agreement. Manual SLSs were considered to be
“short” or “long” if they were below or above the robotic-selected stents,
respectively.
RESULTS Only 35% (21/60) of visually estimated lesions resulted in accurate SLS.
Whereas, 33% (20/60) and 32% (19/60) of the manually-determined SLSs were long
and short, respectively. In 5 cases (8.3%), 1 less stent was placed based on the robotic
lesion measurement being shorter than the visual estimate (TABLE 1).
CONCLUSIONS Manual assessment of lesion length and SLS is highly variable with
65% of the cases being inaccurately measured when compared to objective measures
obtained from the robotic system. The 32% of the cases where lesions were visually
estimated to be short represents cases that often require the use of extra stents after
the full lesion is not covered by 1 stent [Longitudinal Geographic Miss (LGM)].
Further, these data showed that the use of the robotic system prevented the use of
extra stents in 8.3% of the cases. Measurement of lesions with robotic PCI may reduce
measurement errors, need for extra stents, and LGM.
Table 1. Cases with Deﬁnite Stent SavingsCaseVisual
Measurement (mm)Visual Stent Length
Selection (mm)CorPath
Measurement (mm)Final Stent Length
Chosen (mm)1 38 23+18 34.9 382 46 24+24 38.0 383 52 24+28 37.7 384 44 24+20 28.0 325 40 18+23 35.1 38CRT-162
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BACKGROUND The subset of patients with severely reduced left ventricular systolic
function requiring coronary revascularization and valve surgery are at increased risk
for adverse post-operative outcomes. They may beneﬁt from a hybrid approach of
percutaneous coronary intervention (PCI) followed by minimally invasive valve sur-
gery (MIVS), rather than a combined median sternotomy coronary artery bypass graft
and valve surgery.
